Treating liver fibrosis and metabolic dysfunction-associated steatohepatitis: Research ...
Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...
Medscape3 天
Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...
The American Journal of Managed Care2 天
Promising Potential for FGF21 Analogs in MASH Management
Emerging evidence suggests that fibroblast growth factor 21 (FGF21) could play a future part in the treatment of metabolic ...
Inventiva initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Inventiva (IVA) with a Buy rating and $10 price target The firm thinks the company’s oral pan-PPAR agonist ...
News Medical on MSN2 天
Vitamin E significantly improves liver health in MASH patients, new study finds
A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET. The ...